Major S. Korea Pharmas Meet To Resolve Issue Of Bribing Doctors
This article was originally published in PharmAsia News
Executive Summary
S. Korea's leading pharmaceutical companies have begun meeting to resolve the issue of companies offering bribes or other favors to physicians and pharmacists to promote their products. The Korea Pharmaceutical Manufacturers Association said 10 major South Korean drug makers discussed the matter. Among those reported to have been represented were Daewoong, Dong-A Pharmaceutical, Hanmi Pharmaceutical and Yuhan. The move comes in the wake of government threats to prosecute several drug firms for offering bribes. (Click here for more
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.